Welcome to our dedicated page for Nanoviricides news (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on Nanoviricides stock.
NanoViricides, Inc. develops clinical-stage antiviral therapeutics based on its nanoviricide technology and host-mimetic nanomedicine approach. Company news centers on NV-387, its lead broad-spectrum antiviral candidate, including clinical development for MPox, respiratory viral infections, measles and other viral diseases, as well as manufacturing updates for clinical product forms such as NV-387 Oral Gummies.
Recurring updates also cover FDA orphan-drug designation activity, rare-disease regulatory strategy, investor-conference participation and the company’s relationship with TheraCour Pharma for antiviral drug development technology. The news flow is focused on antiviral pipeline progress, regulatory designations and disease-area positioning rather than commercial product sales.
NanoViricides, Inc. (NYSE American: NNVC) reported progress in its drug development against SARS-CoV-2 at the LD 500 investor conference on September 3, 2020. CEO Dr. Anil R. Diwan announced that the company is close to identifying a clinical candidate, leveraging its past work on coronaviruses. NanoViricides has shown effectiveness in animal studies and has completed necessary CMC studies for an IND application to the FDA. The company aims to create a treatment that blocks both re-infection and replication of the virus, with promising results from encapsulating remdesivir in its drug candidates.
NanoViricides, Inc. (NNVC) will present at the LD 500 investor conference on September 3, 2020, at 8:20 AM PDT. The company reports significant advancements in its COVID-19 drug development, claiming efficacy against various coronaviruses, with safe results in animal studies. They are drafting an Investigational New Drug (IND) application to the FDA and intend to re-engage in clinical trials for their shingles drug, NV-HHV-101, targeting a billion-dollar market. Their nanoviricide technology aims to effectively treat enveloped viral infections by mimicking cell surfaces.